Opportunities and Growth in the Antipsychotic Drugs Market
The global market for antipsychotic drugs was valued at approximately USD 18.04 billion in 2023 and is expected to reach about USD 37.40 billion by 2032. This represents a compound annual growth rate (CAGR) of 7.8% from 2024 to 2032.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5147
Key Findings:
- In 2023, second-generation antipsychotic drugs held the largest share of the market, accounting for 65%.
- Schizophrenia was the most common condition treated with antipsychotic drugs, representing 52% of the market in 2023.
- North America was the leading region in the antipsychotic drugs market, holding a 37% share in 2023.
Key Companies in the Antipsychotic Drugs Market
- Otsuka Holdings Co., Ltd. (Otsuka Pharmaceutical Co., Ltd.): A global leader in healthcare, Otsuka is known for developing innovative antipsychotic medications, including the popular drug, Abilify, used to treat conditions like schizophrenia and bipolar disorder.
- Teva Pharmaceutical Industries Ltd.: As one of the largest generic drug manufacturers, Teva also produces antipsychotic treatments such as Quetiapine (Seroquel), which is widely used to manage schizophrenia and other mental health conditions.
- Eli Lilly and Company: Known for its breakthrough drugs, Eli Lilly is a key player in the antipsychotic drugs market, with medications like Zyprexa for schizophrenia and bipolar disorder.
- Dr. Reddy’s Laboratories Limited: A prominent global pharmaceutical company, Dr. Reddy’s manufactures a wide range of generic antipsychotic drugs, providing affordable treatment options for patients worldwide.
- AstraZeneca PLC: This multinational pharmaceutical company offers antipsychotic medications such as Seroquel, a treatment for schizophrenia, depression, and bipolar disorder.
- Johnson & Johnson (Janssen Pharmaceuticals): A leader in the pharmaceutical industry, Janssen, a subsidiary of Johnson & Johnson, markets the widely used antipsychotic drug Risperdal, which is used to treat various mental health conditions.
- Pfizer Inc.: Pfizer is a global pharmaceutical giant with a strong portfolio of medications, including antipsychotic drugs like Geodon, used to treat schizophrenia and bipolar disorder.
- Alkermes Plc.: Specializing in central nervous system treatments, Alkermes develops innovative drugs like Vivitrol, which helps manage schizophrenia and other psychiatric disorders.
- AbbVie Inc. (Allergan Inc.): AbbVie, following its acquisition of Allergan, offers a range of psychiatric treatments, including antipsychotics like the injectable medication, Vraylar, for managing schizophrenia and bipolar disorder.
- Bristol-Myers Squibb: This leading biopharmaceutical company is involved in the development of antipsychotic medications, including those for the treatment of schizophrenia and related disorders.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/antipsychotic-drugs-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5147
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
